Dr. Stefan Moldovan, MD

Dr. Moldovan practices at Ss Vascular in Chula Vista, California.

Dr. Moldovan's NPI, 1245291624, was assigned on March 28, 2006. Dr. Moldovan graduated from Carol Davila University of Medicine and Pharmacy in 1989. Dr. Moldovan holds California license A56200.

Dr. Moldovan's primary practice is Ss Vascular, at 1111 Broadway, Chula Vista, CA 91911 in San Diego County. The practice phone is (619) 567-3556.

Dr. Moldovan's primary practice is Ss Vascular in Chula Vista, California. Dr. Moldovan is also affiliated with Hillcrest Medical Center. The medical group on file is SS Vascular Surgery & Endovascular Therapy. Dmand AI also links Dr. Moldovan to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moldovan practices, 5 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Moldovan's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Moldovan is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Moldovan's licenses on file in 2 states: California and Texas.

Dmand AI lists amputation and blood vessel access for dialysis among the conditions Dr. Moldovan treats.

CMS data shows 328 Medicare services from Dr. Moldovan across 5 procedure codes in 2024, for 220 Medicare patients. Medicare paid $113,642 for them.

CMS counts 220 Medicare patients who saw Dr. Moldovan in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 65% are also on Medicaid. Their average risk score is 4.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Moldovan's median patient age at 63, with 61% women.

In 2024, Dr. Moldovan wrote 70 Medicare Part D claims for 53 patients. 87% of them were for generic drugs. CMS names the drug for 32 of them, across 1 drug with 11 or more claims each, at $204 in total drug cost. In 2023, CMS named 49 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Moldovan for performance year 2024, reported as part of a group. Dr. Moldovan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Moldovan as offering telehealth. CMS counts 121 procedures of varicose vein removal by Dr. Moldovan, more than 86% of the clinicians it reports for that procedure.

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 18 papers to Dr. Moldovan in 2001. The most frequent topics are Insulin, Islets of Langerhans and Insulin Secretion. Dr. Moldovan has published most often in Pancreas. Dr. Moldovan's most frequent co-authors are Edward Harry Livingston, MD, Azmi W. Atiya, MD and Francis Charles Brunicardi, MD.

CMS Open Payments shows 133 general payments to Dr. Moldovan from 43 drug and device companies from 2016 to 2025. Device or supply loans make up the largest share, 87% of the total. AngioDynamics, Inc. paid the most, $42,240.

Dr. Moldovan graduated from Carol Davila University of Medicine and Pharmacy in 1989.

Dr. Moldovan is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.